Meeder Asset Management Inc. acquired a new position in shares of Emergent BioSolutions Inc. (NYSE:EBS – Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 6,051 shares of the biopharmaceutical company’s stock, valued at approximately $41,000.
Other institutional investors and hedge funds also recently modified their holdings of the company. Charles Schwab Investment Management Inc. grew its position in Emergent BioSolutions by 84.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,873,984 shares of the biopharmaceutical company’s stock worth $6,898,000 after buying an additional 1,312,934 shares in the last quarter. Jump Financial LLC acquired a new stake in shares of Emergent BioSolutions during the 4th quarter worth $58,000. Dynamic Technology Lab Private Ltd bought a new position in shares of Emergent BioSolutions in the fourth quarter worth $232,000. Oxford Asset Management LLP acquired a new position in Emergent BioSolutions in the fourth quarter valued at about $67,000. Finally, Los Angeles Capital Management LLC increased its stake in Emergent BioSolutions by 20.1% in the first quarter. Los Angeles Capital Management LLC now owns 193,991 shares of the biopharmaceutical company’s stock valued at $491,000 after acquiring an additional 32,460 shares during the last quarter. 78.40% of the stock is owned by institutional investors.
Emergent BioSolutions Stock Up 3.1 %
Shares of NYSE:EBS opened at $7.87 on Monday. The business has a fifty day simple moving average of $9.68 and a 200 day simple moving average of $6.08. Emergent BioSolutions Inc. has a 12-month low of $1.42 and a 12-month high of $15.10. The firm has a market cap of $416.40 million, a P/E ratio of -0.71 and a beta of 1.60. The company has a quick ratio of 0.54, a current ratio of 1.06 and a debt-to-equity ratio of 1.16.
Analysts Set New Price Targets
Several equities research analysts have weighed in on EBS shares. Rodman & Renshaw restated a “buy” rating and set a $16.00 target price on shares of Emergent BioSolutions in a research note on Friday. Benchmark reaffirmed a “buy” rating and issued a $8.00 price objective on shares of Emergent BioSolutions in a research note on Friday, August 16th.
Get Our Latest Analysis on Emergent BioSolutions
Emergent BioSolutions Company Profile
Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.
See Also
- Five stocks we like better than Emergent BioSolutions
- The Significance of Brokerage Rankings in Stock Selection
- Symbotic’s Double-Bagger Potential as It Hits a Key Inflection
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- High Dividend Yields Make These 2 Shipping Stocks Stand Out
- How Can Investors Benefit From After-Hours Trading
- Can Celsius Stock Rebound? Analysts See 74% Upside Potential
Want to see what other hedge funds are holding EBS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Emergent BioSolutions Inc. (NYSE:EBS – Free Report).
Receive News & Ratings for Emergent BioSolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent BioSolutions and related companies with MarketBeat.com's FREE daily email newsletter.